In the present paper, we report on the use of the heteroduplex PCR technique to detect the presence of clonally rearranged VDJ segments of the heavy chain immunoglobulin gene (VDJH) in the apheresis products of patients with multiple myeloma (MM) undergoing autologous peripheral blood stem cell (APBSC) transplantation. Twenty-three out of 31 MM patients undergoing APBSC transplantation with VDJH segments clonally rearranged detected at diagnosis were included in the study. Samples of the apheresis products were PCR amplified using J H and V H (FRIII and FRII) consensus primers and subsequently analyzed with the heteroduplex technique, and compared with those obtained at diagnosis. 52% of cases yielded positive results (presence of clonally rearranged VDJH segments in at least one apheresis). The presence of positive results in the apheresis products was not related to any pretransplant characteristics with the exception of response status at transplant. Thus, while no one patient with positive apheresis products was in complete remission (CR), negative immunofixation, before the transplant, five cases (46%) with negative apheresis were already in CR at transplant (P = 0.01). The remaining six cases with heteroduplex PCR negative apheresis were in partial remission before transplant. Patients with clonally free products were more likely to obtain CR following transplant (64% vs 17%, P = 0.02) and a longer progression-free survival, (40 months in patients transplanted with polyclonal products vs 20 with monoclonal ones, P = 0.03). These results were consistent when the overall survival was considered, since it was better in those patients with negative apheresis than it was in those with positive (83% vs 36% at 5 years from diagnosis, P = 0.01). These findings indicate that the presence of clonality rearranged VDJH segments is related to the response and outcome in MM transplanted patients. Leukemia
Introduction
Multiple myeloma (MM) is an incurable disease with a median survival of approximately 36 months. Extensive clinical trials with polychemotherapy have not definitively proven to be superior to melphalan and prednisone. 1, 2 The search for more effective therapies has led to the use of high-dose therapy (HDT) followed by autologous stem cell transplantation. Currently, the use of such strategies has improved the quality of response and progression-free survival (reviewed in Ref. 2) and some groups have also reported a longer overall survival. 3 Currently, mobilized peripheral blood (PB) is usually preferable to bone marrow (BM) as a source for autologous stem cell collection, since a more rapid engraftment is achieved with PB. The major aim of PB stem cell (PBSC) mobilization and harvest is to collect a sufficient number of CD34 + cells to guarantee an adequate engraftment and safe post-transplant period. 4 However, less attention has been paid to the theoretical problem of tumor contamination of PBSC collections in patients undergoing transplantation. Consequently, the influence that the presence of myelomatous cells in the leukapheresis has over the outcome of the disease remains unclear. [5] [6] [7] [8] [9] Some studies have suggested that the reinfusion of malignant cells present in the apheresis may contribute to relapse. [10] [11] [12] [13] [14] However, the majority of studies designed to answer this question are based on the use of molecular marker analysis of clonally rearranged segments of the Ig gene, mainly ASO-PCR. These strategies have a very high sensitivity (usually 10 −5 -10 −6 ), which can be too high in MM. Thus, the use of ASO-PCR in MM usually demonstrates the presence of clonally rearranged cells in the majority of autologous harvests. 9, [15] [16] [17] [18] In addition, these techniques are complicated and time-consuming, which would present problems at clinical level. 16, 18, 19 Very recently, Mitterer et al 20 have shown that the presence of a clonal pattern in the B cell-enriched fraction of the PBSC harvests was related to a poorer response to the HDT in MM patients transplanted with purged APBSC. In their study, they used GeneScanning analysis, whose sensitivity is much lower than the ASO-PCR (10 −2 to 10 −4 ). It is possible that this low sensitivity can be more relevant when using an automated sequencer, but this equipment is not available in many centers.
We have previously used a very simple PCR-based technique that allows the identification of VDJ clonally rearranged segments of the IgH gene present in samples from MM patients with sensitivity ranging between 10 −2 to 10 −4 . 21 This technique 22 consists of the use of PCR amplification with consensus primers and the analysis of the amplified products after heteroduplex formation in polyacrylamide gels without the need for expensive equipment. In the present study, we report on the use of this technique to analyze the presence of clonally rearranged cells in the apheresis products of patients undergoing autologous PBSC transplantation. The heteroduplex PCR analysis of VDJH segments was able to detect the presence of residual clonally rearranged cells in 52% of patients, and the detection of such cells was capable of predicting the response to HDT and the outcome of disease after transplantation.
Patients and methods

Patients and therapeutic protocol
Thirty-one patients from a single institution under the age of 65 years were enrolled on a high-dose chemotherapy program with a single PBSC autografting. Diagnosis of MM was made according to the criteria of the Chronic Leukemia Myeloma Task Force. 23 The apheresis products could be analyzed in 23 of them, since VDJH clonal rearrangements could be detected in bone marrow samples at diagnosis. The remaining eight patients (25%) harbored VDJH segments which could not be amplified by PCR at diagnosis. These patients have previously been reported in part. 21, 24 Twenty-three patients whose samples yielded an analyzable VDJH clonally rearranged segment were included in the analysis. Nineteen of them were transplanted within a protocol which includes the transplantation as part of the front-line therapy. 24 The remaining four patients were transplanted after a relapse and subsequent response to salvage therapy (second partial response). The clinical and biological characteristics of these valid patients at diagnosis and at transplantation are shown in Table 1 .
The harvests were carried out after four to six cycles of polychemotherapy (VBCMP/VBAD). Twelve patients were mobilized with G-CSF alone (10 g/kg), followed by PBSC collection 5 days after growth factor had been started. The remaining 11 patients were mobilized with 3 g/m 2 of cyclophosphamide (CP), followed by G-CSF (10 g/kg). In these 11 cases, the collection was started when the peak of CD34 + cells in PB was detected by flow cytometry as previously described 4 (all of them between 11 and 14 days after infusion of cyclophosphamide). The apheresis were collected in a Fenwal CS3000 machine (Baxter Biotech, Deerfield, IL, USA) and until at least 1 × 10 6 CD34 + cells had been collected. Sixtyeight aphereses were harvested in these patients, with a median of two per patient (range, 1-7). Five patients required extra mobilization because of an insufficient number of cells in the first process. The conditioning regimen was melphalan 200 mg/m 2 in all cases. After transplantation, all patients were scheduled to receive maintenance treatment with escalating doses of IFN until 3 × 10 6 U/day, 3 days per week, with dexamethasone 40 mg/day, 4 days every 3 weeks. 
Hematopoietic engraftment and response criteria
Granulocyte recovery was defined as the first of 3 consecutive days with granulocyte counts above 0.5 × 10 9 /l. Recovery of platelets was defined as the first of 7 consecutive days with a platelet count of Ͼ20 × 10 9 /l and no platelet transfusion requirements.
The criteria for response evaluation following standard treatment and transplantation were those proposed by Bladé et al 25 considering the following types of response: complete response (CR), partial response (PR), minimal response (MR), no change (NC) and progressive disease (PD). A negative immunofixation, both in serum and urine, was required to assess a CR. The best response status achieved in the 12 months after high-dose therapy was used for evaluation of the response to transplantation. The same criteria were used to define the response status at transplant, but in the evaluation performed immediately before HDT.
Overall survival (OS) was considered from the time of diagnosis until death. Overall survival from transplantation (OST) was considered from the time of infusion of PBSC until death. Progression-free survival (PFS) was considered only for patients who achieved some kind of response (CR, PR, MR or NC) from the time point in which response was noted after transplantation (day +90) until progression or relapse.
DNA extraction and PCR amplifications at diagnosis
Bone marrow aspirate specimens were obtained during the diagnostic procedures in all 31 MM patients. PC were counted based on strong positivity of the CD38 antigen and the presence of intracellular single immunoglobulin light chain (Ig or Ig). 26 Standard proteinase K digestion, phenol-chloroform extraction and ethanol precipitation were used to isolate high 1495 molecular weight DNA. The quality of DNA was tested by PCR amplification of the ABL gene.
PCR analyses of the VDJ region of the Ig heavy chain gene (VDJH) were performed with 500 ng of genomic DNA. The consensus primer pairs of the VH and JH segments as well as the PCR conditions have been previously described. 21, 27 For heteroduplex analysis, PCR products were denatured at 94°C for 5 min and subsequently cooled at 4°C to induce duplex formation, and the homo-and/or heteroduplexes were electrophoresed on 6% polyacrylamide gels. The visualization of products was made by silver nitrate staining.
Apheresis and detection of residuals cells
Samples from 68 apheresis of the 23 valid patients were analyzed for the presence of the same clonally rearranged VDJH segment already detected at diagnosis. The procedure was the same as the one described above for diagnosis, but the duplex/heteroduplex formation was made at 40°C in order to increase the sensitivity. 21 PCR products of the apheresis samples were run parallel to the PCR product obtained at diagnosis in order to assess the same electrophoretic characteristics of the products. In addition, all experiments were carried out at least twice, together with positive and negative controls, in order to avoid false negative and positive results. Figure 1 shows a representative example of the heteroduplex assay.
This technique has a sensitivity of 10 −2 to 10 −4 . This range mainly depends on the presence of polyclonal B cells on the sample, which act as a confusing background. Thus, when the sample has a high polyclonal background (ie clonal samples on reactive tonsils) the sensitivity is 10 −2 . By contrast, when the polyclonal background is low (ie dilutions in granulocytes) the sensitivity can reach a level of 10 −4 . However, in repeated experiments, the most frequent level of detection was 5 × 10 −4
, so we can establish a threshold of detection which should be interpreted as follows: the absence of clonal bands means that the number of tumor cells is below one tumor per 2000 normal cells. This level of sensitivity can be accepted in this study because the number of polyclonal B cells in the apheresis from MM patients is low, especially after treatment. Thus, the median number of CD19 + cells detected by flow cytometry in 35 apheresis from 14 patients tested, was 0.61% with a range between 0.07 and 2.10%. This data confirm that the polyclonal background in the apheresis
Figure 1
Example of a heteroduplex PCR analysis of apheresis products from one MM patient. M, molecular weight marker; A1, A2 and A3, apheresis samples of three consecutive days; Dx, diagnostic bone marrow sample of this patient; 10 −2 to 10
, dilution series of the diagnostic bone marrow sample from this patient; C, negative control.
Leukemia of MM patients is very low, so the sensitivity of the heteroduplex technique is 5 × 10 −4 in these samples.
Statistical methods
To estimate the statistical significance of the differences observed in patients for continuous variables, the Mann-Whitney U and Kruskal-Wallis tests were employed, using the SPSS statistical software (SPSS Inc, Chicago, IL, USA). The Chisquare test (crosstabs, SPSS) was used for comparison of dichotomic variables between groups. Survival curves were plotted according to the method of Kaplan and Meier, and compared using the log-rank test (survival, SPSS).
Results
Patient outcome
The transplant was successfully performed in all cases and no transplant-related deaths were noted in this subset of patients. The mean hospitalization period was 20 days. Almost all patients responded to transplant. Nine of them (39%) achieved CR, with negative serum and urine IF. Thirteen patients achieved PR and one patient achieved a reduction of the peak between 25% and 50% (MR). At the time of publication, 12 patients had progressed or relapsed, with a global median progression-free survival from transplantation of 36 months. In a multivariate analysis, the main predictor for the progression-free survival and overall survival from the transplant was the response to the high-dose therapy or, if excluded the response status at the time of transplant. Figure 2 shows the PFS according to it (CR, PR or 'other'). The median PFS was not reached for patients transplanted in CR, 33 months for patients transplanted in PR and 3 months for those transplanted in other status (without response, stable or progressive disease), this having an impact on the overall survival from transplant. However, the differences were statistically significant only for patients transplanted without response, while they were not statistically significant between those transplanted in CR or PR. Eight patients had died due to disease progression, this leading to a median OST of 40 months (63 months OS from diagnosis).
Figure 2
Progression-free survival curves according to the response status at the time of transplantation.
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Heteroduplex PCR of VDJH segments in apheresis products
Sixty-eight apheresis samples from the 23 valid patients were analyzed. Twenty-nine (42%) products displayed the same clonal band observed at diagnosis, meaning that 12 patients (52%) had a positive result in at least one apheresis product, indicating the presence of tumor cells in the product that was finally used for the reinfusion.
PCR results in the apheresis products and pretransplant characteristics
There were no statistically significant differences at diagnosis between those patients with heteroduplex PCR positive results in the apheresis products and those with negative results (Table 2 ). In addition, the presence of a positive result was not related to any disease characteristics at transplant, with the exception of response status at transplant (Table 2) . Thus, while in the 11 patients with negative apheresis product there Table 2 Clinico-biological characteristics of the patients according to the detection of clonal cells in the apheresis products Positive (n = 12) Negative (n = 11) P were five (46%) in CR, there were no cases in CR within the 12 patients with positive apheresis products ( Table 2 ). In addition, the type of mobilization did not influence the heteroduplex PCR result in the apheresis (P = 0.137). The mobilization regimen (with or without chemotherapy) and the number of cycles (4, 5 or 6) received prior to the transplant had no influence on the presence or absence of clonal bands in the apheresis products. In addition, the fact of being transplanted in first or second response (after a relapse and reinduction chemotherapy) did not significantly influence the collection of positive or negative apheresis. Four patients were transplanted in second response, and three of them yielded positive apheresis while this was negative in the other patient.
PCR results in the apheresis products and posttransplant outcome
Those patients without the presence of clonally rearranged cells in the apheresis products were more likely to obtain CR
Figure 3
Progression-free survival curves according to the presence of positive or negative heteroduplex PCR apheresis products.
following transplant than those with positive aphereses. Thus, in the group of patients with negative apheresis, the response was CR in 64%. By contrast, the CR rate was only 17% in the group with positive apheresis (P = 0.022) ( Table 2) .
The progression-free survival was longer in those patients transplanted with negative than in those with positive apheresis (median PFS of 40 vs 20 months; 39% vs 0% free of progression at 5 years after transplant; log rank, P = 0.035) ( Table  2 ) (Figure 3 ). In addition, the OST was longer in those patients with negative than in those with positive apheresis products (86% vs 20% alive at 5 years after transplant; log rank, P = 0.024) ( Table 2 ) (Figure 4) . Interestingly, although this study was not designed to detect differences in the overall survival from diagnosis, there were statistically significant differences between the two groups too. Thus, while the OS was 83% at 5 years from diagnosis in the group of patients transplanted with PCR negative apheresis, this survival was only 36% in the group transplanted with positive apheresis (log rank, P = 0.0173) ( Figure 5 ).
In the multivariate analysis, the presence or absence of clonal bands in the apheresis products only showed a trend to prognostic value (P = 0.138), since their independent influence was hampered by the impact of response to transplant (the only independent prognostic factor). However, we have to take into account that this analysis was made in 23 patients, and the figure could be different if more patients were added to the study.
Figure 4
Overall survival from transplant curves according to the presence of positive or negative heteroduplex PCR apheresis products.
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Figure 5
Overall survival from diagnosis curves according to the presence of positive or negative heteroduplex PCR apheresis products.
Discussion
In this article, 12 out of 23 autotransplanted patients displayed the presence of clonally rearranged cells in the apheresis products used for transplantation. These cells had the same amplification product already detected at diagnosis. This study demonstrates that the apheresis products frequently contain monoclonal tumor cells in MM. Other groups have reported similar results, 9,13,28-30 although they usually detect myelomatous cells in the apheresis samples with a higher frequency than we report here. This difference can be explained by the methodology, since we used a technique with a smaller sensitivity than the one they used (5 × 10 −4 for the heteroduplex PCR technique vs 10 −5 -10 −6 for ASO-PCR). Along the same lines, the use of the fingerprinting 12, 31, 32 techniques and GeneScanning, 20 which have a similar sensitivity to the heteroduplex PCR analysis (10 −3 -10 −4 ), have reported similar results to ours.
Whether or not the detection of clonally rearranged cells in the apheresis products has a clinical or biological significance is unclear in the literature. The majority of studies performed have used highly sensitive techniques, such as ASO-PCR, which are able to detect clonal products in practically 100% of patients analyzed, 18, 29, 33 who, nevertheless, have heterogeneous outcome after transplantation. In our study, we have used a less sensitive technique, which detects clonal products in about one half of patients, thus allowing comparisons between them. Therefore, we have found a correlation between the disease status at the apheresis procedure and the presence of clonal cells. This indicates that we should expect to collect apheresis contaminated with tumor cells if the disease status is not very good, following the premise: the poorer status, the more contaminated the apheresis.
In addition, we have also found a correlation between the presence of contaminated apheresis and the outcome after transplant. Thus, the CR rate was 64% in the group of patients transplanted with apheresis free of clonal cells, while it was 17% in those transplanted with contaminated apheresis (P Ͻ 0.05). This relationship was also observed in the outcome, since the PFS, OST and OS were longer if the apheresis product was negative. These results have not been found with the use of more sensitive techniques that have been unable to predict response, since virtually all apheresis products contain positive results while the patients finally had very different outcomes. 18, 28, 29, 33 By contrast, other methods with relatively lower sensitivity have been shown to be more predictive. In this way, Mitterer et al 20 have recently shown that the pres-ence of a monoclonal pattern in the B cell fraction of PBSC harvest is related to poorer response. This finding was made by using GeneScanning analysis, a specific method with a sensitivity of around to 10 −2
. 34 These results are consistent with those obtained in other diseases. Thus, the RT-PCR to detect the t(15;17) in acute promyelocytic leukemias is very predictive of relapse when strategies with a relatively low level sensitivity (ෂ1 × 10 −3 ) are used. 35 In this way, our own group has found that the most predictive cut-off value for minimal residual disease (MRD) in acute myeloid leukemia detected by flow cytometry is 5 × 10 −3 . 36 So those techniques with this level of sensitivity would be very predictive.
Our study shows that the collection of PBSC products with low numbers of contaminating clonal cells (less than one clonal cell per 2000 normal cells) favors a better response to transplant, a better PFS and a better survival. Whether this correlation is related to early relapse/progression derived from tumor cells reinfused after transplantation or from tumor cells which have not been eliminated with HDT and remain in the patient is not yet clear. The fact that no differences between patients with positive or negative apheresis could be seen at diagnosis favors the hypothesis that relapses and progressions could be derived from cells contaminating the apheresis reinfused after the conditioning regimen. On the other hand, the relationship between the apheresis clonality and the response status before transplant would suggest that the better outcome obtained in those patients with a polyclonal apheresis is due to a better reduction of tumor load more than to the absence of contaminating cells in the reinfusion product.
In summary, our study shows that the presence of clonally rearranged cells in the apheresis products for autologous PBSC is frequent in MM. In addition, the detection of relatively high quantities of tumor cells in these products by heteroduplex PCR analysis is associated with a poorer disease status at mobilization and responses to transplant, as well as short PFS and, probably, with a shorter overall survival.
